Progress in studies on the correlation between IGF-1 level and thyroid diseases in diabetic patients

doi:10.3877/cma.j.issn.2095-655X.2022.02.008

Abstract

Abstract:

Insulin-like growth factor 1 (IGF-1) is one of the most important and extensive functional cytokines the body. It can promote growth and development, substance metabolism, cell differentiation and proliferation. The amino acid sequence of IGF-1 is homologous to insulin, so it has hypoglycemic effect similar to insulin. Previous studies have shown that serum IGF-1 levels are lower in the people with diabetes than those in the people without diabetes. At the same time, IGF-1 can stimulate thyroid function directly or indirectly, and it can affect iodine uptake and organic synthesis together with the thyrotropin (TSH), leading to abnormal thyroid function. In recent years, the incidence of thyroid disease in patients with diabetes is increasing year by year. This paper reviews the research progress of the correlation between IGF-1 levels and thyroid diseases in diabetic patients.

Key words: Diabetes mellitus, Insulin-like growth factor 1, Thyroid diseases

Ruowei Luan, Mei Zhang. Progress in studies on the correlation between IGF-1 level and thyroid diseases in diabetic patients[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(02): 109-112.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.02.008

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I02/109

References 38

[1]	Ogurtsova K, da Rocha Fernandes JD, Huang Y，et al.IDF diabetes atlas：global estimates for the prevalence of diabetes for 2015 and 2040[J]．Diabetes Res Clin Pract，2017(128):40-50.DOI：10.1016/j.diabres.2017.03.024.
[2]	牛玲，李博一，张建伟，等．昆明地区糖尿病患者甲状腺结节患病率[J]．昆明医科大学学报，2017，38(5):78-82.
[3]	Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F，et al.The incidence and prevalence of thyroid dysfunction in europe：a meta-analysis[J]．J Clin Endocrinol Metab，2014，99(3):923-931.DOI：10.1210/jc.2013-2409.
[4]	Centeno Maxzud M, Gómez Rasjido L, Fregenal M，et al.Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus[J]．Medicina(B Aires)，2016，76(6):355-358.
[5]	Subekti I, Pramono LA, Dewiasty E，et al.Thyroid dysfunction in type 2 diabetes mellitus patients[J]．Acta Med Indones，2017，49(4):314-323.
[6]	Wang H, Zhang H, Cao F，et al.Protection of insulin-like growth factor 1 on experimental peripheral neuropathy in diabetic mice[J]．Mol Med Rep，2018，18(5):4577-4586.DOI：10.3892/mmr.2018.9435.
[7]	Mancuso E, Mannino GC, Fatta CD，et al.Insulin-like growth factor-1 is a negative modulator of glucagon secretion[J]．Oncotarget，2017，8(31):51719-51732.DOI：10.18632/oncotarget.18514.
[8]	Maximus PS.Insulin like growth factor 1 is linked to higher cardiovascular risk score in adults with type 2 diabetes mellitus and chronic kidney disease[J]．Diabetes Metab Syndr，2019，13(4):2613-2618.DOI：10.1016/j.dsx.2019.07.008.
[9]	Aguirre GA, González-Guerra JL, Espinosa L，et al.Insulin-like growth factor 1 in the cardiovascular system[J]．Rev Physiol Biochem Pharmacol，2018(175):1-45.DOI：10.1007/112_2017_8.
[10]	Nederstigt C, Corssmit EP, de Koning EJ，et al.Incidence and prevalence of thyroid dysfunction in type 1 diabetes[J]．J Diabetes Complications，2016，30(3):420-425.DOI：10.1016/j.jdiacomp.2015.12.027.
[11]	Gu Y, Li H, Bao X，et al.The relationship between thyroid function and the prevalence of type 2 diabetes mellitus in euthyroid subjects[J]．J Clin Endocrinol Metab，2017，102(2):434-442.DOI：10.1210/jc.2016-2965.
[12]	蒋正，陈敏华．糖尿病合并甲状腺功能异常的相关危险因素研究[J]．中国医学工程，2018，26(3):4-6.DOI：10.19338/j.issn.1672-2019.2018.03.002.
[13]	郝鑫，施秉银，赵新.2型糖尿病住院患者甲状腺功能分析[J]．中国现代医药杂志，2015，17(1):74-75.DOI：10.3969/j.issn.1672-9463.2015.01.038.
[14]	许晓燕，李肃宁.2型糖尿病合并甲状腺疾病的临床分析[J]．宁夏医学杂志，2016，38(9):795-797.DOI：10.13621/j.1001-5949.2016.09.0795.
[15]	姜晓洪．中老年2型糖尿病合并甲状腺功能异常患者的临床特点分析[J]．保健医学研究与实践，2021，18(3):65-68.DOI：10.11986/j.issn.1673-873X.2021.03.012.
[16]	胡晓黎.2型糖尿病合并甲状腺功能异常的临床分析[J]．特别健康，2019(36):64.
[17]	Subekti I, Pramono LA, Dewiasty E，et al.Thyroid dysfunction in type 2 diabetes mellitus patients[J]．Acta Med Indones，2017，49(4):314-323.
[18]	Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio：a mechanistic insight into the metabolic [J]．Clin Sci(Lond)，2009，116(6):507-512.DOI：10.1042/CS20080382.
[19]	Åsvold BO, Vatten LJ, Midthjell K, et al. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism：11-year follow-up of the HUNT Study in Norway[J]．J Clin Endocrinol Metab，2012，97(1):93-99.DOI：10.1210/jc.2011-1724.
[20]	Kadiyala R, Peter R, Okosieme OE.Thyroid dysfunction in patients with diabetes：clinical implications and screening strategies[J]．Int J Clin Pract，2010，64(8):1130-1139.DOI：10.1111/j.1742-1241.2010.02376.x.
[21]	Shapiro MR, Wasserfall CH, McGrail SM，et al.Insulin-like growth factor dysregulation both preceding and following type 1 diabetes diagnosis[J]．Diabetes，2020，69(3):413-423.DOI：10.2337/db19-0942.
[22]	Drogan D, Schulze MB, Boeing H，et al.Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus：results from the EPIC-potsdam study[J]．Am J Epidemiol，2016，183(6):553-560.DOI：10.1093/aje/kwv188.
[23]	孙娜娜，韩立坤．男性2型糖尿病合并良性甲状腺结节患者的内分泌激素特征[J]．中国医科大学学报，2019，48(6):515-518,524.
[24]	Yamanaka Y, Wilson EM, Rosenfeld RG，et al.Inhibition of insulin receptor activation by insulin-like growth factor binding proteins[J]．J Biol Chem，1997，272(49):30729-30734.DOI：10.1074/jbc.272.49.30729.
[25]	王凤玲，邓海荣，刘玉枝，等．碘致甲状腺功能异常及其与IGF-1和IGFBP-3表达的研究进展[J]．医学综述，2018，24(9):1676-1680,1686.DOI：10.3969/j.issn.1006-2084.2018.09.003.
[26]	Martin S, Sirbu A, Betivoiu M, et al. IGF1 deficiency in newly diagnosed Graves′ disease patients[J]．Hormones (Athens)，2015，14(4):651-659.DOI：10.14310/horm.2002.1577.
[27]	Morgan SJ, Neumann S, Marcus-Samuels B，et al.Thyrotropin and insulin-like growth factor 1 receptor crosstalk Upregulates sodium-iodide Symporter expression in primary cultures of human Thyrocytes[J]．Thyroid，2016，26(12):1794-1803.DOI：10.1089/thy.2016.0323.
[28]	Krieger CC, Boutin A, Jang D, et al. Arrestin-beta-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk[J]．Endocrinology，2019，160(6):1468-1479.DOI：10.1210/en.2019-00055.
[29]	Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]．N Engl J Med，2020，382(4):341-352.DOI：10.1056/NEJMoa1910434.
[30]	焦丽静，闫园园，王宝镯，等．血清胰岛素样生长因子-1与2型糖尿病患者甲状腺结节TI-RADS分级的相关性研究[J]．华北理工大学学报(医学版)，2020，22(5):382-386,392.DOI：10.19539/j.cnki.2095-2694.2020.05.009.
[31]	Altas A, Kuzu F, Arpaci D，et al.The clinical values of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels in blood and thyroid nodules[J]．Int J Endocrinol，2017(2017):3145234.DOI：10.1155/2017/3145234.
[32]	Schmidt JA, Allen NE, Almquist M, et al. Insulin-like growth factor-1 and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition[J]．Cancer Epidemiol Biomarkers Prev，2014，23(6):976-985.DOI：10.1158/1055-9965.EPI-13-1210-T.
[33]	Lawnicka H, Motylewska E, Borkowska M，et al.Elevated serum concentrations of IGF-1 and IGF-1R in patients with thyroid cancers[J]．Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub，2020，164(1):77-83.DOI：10.5507/bp.2019.018.
[34]	余彩英．糖尿病与甲状腺功能异常之间的关系分析[J]．心理月刊，2020，15(10):169.DOI：10.19738/j.cnki.psy.2020.10.145.
[35]	廖明，尹琦，梁江燕，等．胰岛素样生长因子结合蛋白相关蛋白1与2型糖尿病胰岛素抵抗的相关性研究[J]．糖尿病新世界，2017，20(9):17-19,62.DOI：10.16658/j.cnki.1672-4062.2017.09.017.
[36]	Kimura T, Van Keymeulen A, Golstein J，et al.Regulation of thyroid cell proliferation by TSH and other factors：a critical evaluation of in vitro models[J]．Endocr Rev，2001，22(5):631-656.DOI：10.1210/edrv.22.5.0444.
[37]	闫园园，魏剑芬，李世超，等．血清胰岛素样生长因子-1与糖尿病合并甲状腺疾病的相关性[J]．广东医学，2019，4(5):647-651.DOI：10.13820/j.cnki.gdyx.20182780.
[38]	魏剑芬，闫园园，王宝镯，等．糖尿病合并甲状腺机能亢进症患者血清IGF-1水平的变化 [J]．华北理工大学学报(医学版)，2019，21(1):7-10,15.DOI：10.19539/j.cnki.2095-2694.2019.01.002.

Please choose a citation manager

Content to export